Our study found significantly higher median CRP levels in the endpoint group (5.00 mg/L) versus the non-endpoint group (1.10 mg/L), likely reflecting greater inflammation associated with higher SLEDAI scores and proliferative LN prevalence in the endpoint group. Here, CRP is linked to lobular neoplasia.